Pal-GHK, Biopeptide CL
Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
Palmitoyl Tripeptide-1 is a cosmetic peptide ingredient — the collagen-stimulating half of the Matrixyl 3000 combination. It is a lipid-modified version of the naturally occurring GHK peptide, with a fatty acid chain attached to improve skin penetration. It has no pharmaceutical approval.
1 published studies: 1 human, 0 animal, 0 in-vitro, 0 reviews
Palmitoyl Tripeptide-1 has no pharmaceutical authorisation. It is used as a cosmetic ingredient both independently and as a component of Matrixyl 3000 (#135). A small vehicle-controlled study (15 subjects) reported significant improvements in wrinkle depth and skin roughness over 4 weeks.
Among cosmetic peptides, Pal-GHK has a reasonable evidence base for topical skin appearance effects. It is a topical cosmetic ingredient.
Research suggests Pal-GHK signals fibroblasts to produce collagen and other extracellular matrix proteins through the same matrikine pathway as its parent GHK peptide. The palmitoyl chain enhances membrane interaction and skin penetration. In vitro studies report significant increases in multiple collagen types.
Research suggests a small controlled study (15 participants) showed significant improvements in wrinkle depth and skin roughness over 4 weeks. Laboratory data for collagen stimulation are strong and consistent. A claimed 100-fold potency advantage over retinoic acid in UV protection requires in vivo confirmation. All studies are manufacturer-sponsored with small sample sizes. The compound trades better skin penetration (via the palmitic acid chain) against loss of the copper-dependent antioxidant activity of its parent GHK-Cu. It is a topical cosmetic ingredient.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Epitalon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. Animal lifespan studies in mice reported by the Khavinson group form the core evidence base. The telomerase activation claims are based on in vitro studies and mouse models from a single research programme. Independent replication of the key findings has not been published. The relationship between in vitro telomerase activation and any clinical outcome in humans is not established. Products available through unregulated channels lack pharmaceutical quality assurance.
FOXO4-DRI has no marketing authorisation. No human clinical trials have been conducted. The evidence comes from a single high-profile publication (Cell, 2017) demonstrating effects in three mouse models. The senolytic field is an active area of pharmaceutical research, but FOXO4-DRI faces significant challenges for clinical translation, including its large size (46 amino acids), manufacturing complexity, and the absence of human pharmacokinetic or safety data. Products available through unregulated channels — which would need to reliably synthesise a 46-amino-acid all-D-amino-acid peptide — face exceptional quality assurance challenges.
